Brainstem gliomas that harbor IDH mutations, on the other hand, may respond to hypomethylating agents, such as 5-azacytidine and decitabine, both FDA approved for myelodysplastic syndrome. This evidence concerns the gene IDH2 and myelodysplastic syndrome.